2. Induced Disease Models Products Neuronal Signaling GPCR/G Protein Metabolic Enzyme/Protease
  3. Nervous System Disease Models Dopamine Receptor Endogenous Metabolite
  4. Parkinson's Disease Models
  5. L-DOPA

L-DOPA  (Synonyms: Levodopa; 3,4-Dihydroxyphenylalanine)

Cat. No.: HY-N0304 Purity: 99.98%
COA Handling Instructions

Molarity Calculator

L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.

For research use only. We do not sell to patients.

L-DOPA Chemical Structure

L-DOPA Chemical Structure

CAS No. : 59-92-7

Size Price Stock Quantity
200 mg USD 60 In-stock
1 g USD 84 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 18 publication(s) in Google Scholar

Other Forms of L-DOPA:

L-DOPA Related Antibodies

Top Publications Citing Use of Products

View All Dopamine Receptor Isoform Specific Products:

View All Isoforms
Dopamine Receptor D1 Receptor D2 Receptor D3 Receptor D4 Receptor D5 Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

IC50 & Target

Human Endogenous Metabolite

 

In Vivo

L-DOPA can be used to create movement disorder models. In adult common marmosets, after oral administration of L-DOPA (20/5 mg/kg), the Tmax in plasma is 30 minutes, and the Tmax in striatal extracellular fluid (ECF) is 60-90 minutes. The mean Cmax of L-DOPA in plasma is 20.3 μM, while the mean Cmax in striatal ECF is 442.9 nM, representing about 2.2% of the plasma level[6].

Induction of dyskinesia model[5]
Background
L-DOPA-induced dyskinesia results from a pulsatile stimulation of brain dopamine (DA) receptors, triggering a complex cascade of molecular and synaptic alterations within the basal ganglia[5].
Specific Mmodeling Methods
Mice: C57Bl/6 mice • male • 8 weeks (period: 21 days)
Administration: 20 mg/kg • ip • once daily for 21 days
Note
(1) sustained unilateral 6-OHDA injections in the striatum before starting treatment.
(2) Injection volume is 10mL/kg body weight.
Modeling Indicators
Behavioral changes: Shows developed abnormal involuntary movements (AIMs) affecting the head, trunk and forelimb on the side contralateral to the lesion.
Correlated Product(s): Oxidopamine hydrochloride (HY-B1081)
Opposite Product(s): Oxidopamine hydrobromide (HY-B1081A)

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 7-week-old C57BL/6J mice[3]
Dosage: 20 mg/kg
Administration: Orally
Result: Reduced Rotenone-induced motor dysfunction.
Animal Model: Sprague-Dawley rats (male 100-150 g)[4]
Dosage: 10, 30, 50, 70, and 100 mg/kg
Administration: Orally
Result: Reverses tactile, cold and heat allodynia in neuropathic rat without any side effect.
Clinical Trial
Molecular Weight

197.19

Formula

C9H11NO4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

N[C@@H](CC1=CC(O)=C(C=C1)O)C(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, stored under nitrogen

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

0.1 M HCL : 20 mg/mL (101.43 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C)

DMSO : 2 mg/mL (10.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 1 mg/mL (5.07 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.0713 mL 25.3563 mL 50.7125 mL
5 mM 1.0143 mL 5.0713 mL 10.1425 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 3.33 mg/mL (16.89 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.98%

COA (246 KB) RP-HPLC (230 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO / 0.1 M HCL 1 mM 5.0713 mL 25.3563 mL 50.7125 mL 126.7813 mL
5 mM 1.0143 mL 5.0713 mL 10.1425 mL 25.3563 mL
DMSO / 0.1 M HCL 10 mM 0.5071 mL 2.5356 mL 5.0713 mL 12.6781 mL
0.1 M HCL 15 mM 0.3381 mL 1.6904 mL 3.3808 mL 8.4521 mL
20 mM 0.2536 mL 1.2678 mL 2.5356 mL 6.3391 mL
25 mM 0.2029 mL 1.0143 mL 2.0285 mL 5.0713 mL
30 mM 0.1690 mL 0.8452 mL 1.6904 mL 4.2260 mL
40 mM 0.1268 mL 0.6339 mL 1.2678 mL 3.1695 mL
50 mM 0.1014 mL 0.5071 mL 1.0143 mL 2.5356 mL
60 mM 0.0845 mL 0.4226 mL 0.8452 mL 2.1130 mL
80 mM 0.0634 mL 0.3170 mL 0.6339 mL 1.5848 mL
100 mM 0.0507 mL 0.2536 mL 0.5071 mL 1.2678 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

L-DOPA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

L-DOPA59-92-7Levodopa 3,4-DihydroxyphenylalanineDopamine ReceptorEndogenous MetaboliteOrallyprecursorneurotransmittersdopamineblood-brainbarrieranti-allodynicParkinsonInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
L-DOPA
Cat. No.:
HY-N0304
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.